Pancreatic Cancer

New Protocol: Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer

2023-06-07

  • Study

    Prospective, multicenter, double-blinded, randomized phase 3 study
    Previously untreated metastatic pancreatic adenocarcinoma
    Nimotuzumab + Gemcitabine (n=41) vs. Gemcitabine (n=41)

  • Efficacy

    mOS: 10.9 vs 8.5 mos, HR:0.66, p=0.080
    mPFS: 4.2 vs. 3.6 mos, HR:0.60, p=0.040
    mTTP: 4.7 vs. 3.7 mos, HR:0.67, p=0.311
    DCR: 68.3% vs. 63.4%

  • Safety

    Grade≥ 3: Neutropenia (46%), hypertension (15%), dry skin, pruritus (13%), anemia (10%)

    • J Clin Oncol AUG 30; 2023

    Qin Shukui et al. Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer

    http://doi.org/10.1200/JCO.22.02630

    Reviewed by Elvin CHALABİYEV, MD on SEP 10, 2023